
Lupin Q1 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- India business is back to double-digit growth, with 11.5% QoQ and 10.2% YoY growth, and consistent above-market growth expected from Q2 onwards due to sales force expansion.
- US business margins improving for fourth consecutive quarter, with new product launches (Tiotropium, Darunavir exclusivity) and expected approvals bolstering revenue growth.
- API portfolio growth at 4.5% QoQ and 32.1% YoY, with new product launches contributing to future growth.
- Fostair product in Europe is growing well: UK sales strong, recent Germany launch, with fiscal year '25 expected as peak sales year contributing a good percentage of European revenues.
- Injectable business pipeline expected to build into a multi-$100 million business over 2-3 years, with current filed pipeline supporting $100 million plus opportunity.
- Growth in chronic therapies (Respiratory, Cardiac, Diabetes) and emerging segments like Women’s Health, GI, Ophthalmic is anticipated; Oncology and CNS remain underrepresented with headroom to grow.
- PenG prices expected to stay high but not increase further; incremental growth will come from new products.
See what Lupin management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Lupin management said on order book — free account, 30 seconds.
Capex plans
Yes- Lupin has incorporated a subsidiary, Lupin Manufacturing Solutions, for contract development and manufacturing (CDMO) activities, indicating possible future investments in this area, although specific plans are still being finalized.
- The parent company plans to allocate the lion’s share of incremental capital towards the core India business and other high-growth geographies, with the CDMO subsidiary expected to attract external capital as well.
- There is no immediate large regional expansion planned; focus is on stabilizing existing divisions in India with one more division potentially launching this fiscal year.
- R&D spend (~INR 1,400 crores annually) remains significant with over 50% on complex assets like inhalation, injectables, and biosimilars, indicating ongoing strategic investment in pipeline development.
- Lupin has curtailed NCE discovery spend but continues clinical trials on select pipeline programs through low-cost efforts.
- Investments include building bigger brands within India and scaling an extra urban pilot division.
Track Lupin — get its next earnings analysis in your feed
How does Lupin rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Lupin rank in Pharmaceuticals & Biotechnology?
Compare Lupin against every Pharmaceuticals & Biotechnology company (Q1 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Lupin's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem